All In Biotech

Drug Trial Radar · NCT03671018

A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma

An Open-Label, Randomized, Multicenter, Phase Ib/II Trial Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in Patients With B-Cell Non-Hodgkin Lymphoma

Last checked: Nov 20, 2026Latest source record: Nov 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

422

Planned (sponsor's estimate)

Start

Sep 25, 2018

Primary completion

Jan 30, 2024

Study completion Jul 20, 2025

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Sep 14, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of intravenous (IV) or subcutaneous (SC) mosunetuzumab in combination with polatuzumab vedotin in participants with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL). It will consist of a dose finding portion followed by an expansion phase for second line or later (2L+) participants with relapsed or refractory (R/R) DLBCL and 2L+ R/R FL. In addition, subcutaneous mosunetuzumab in combination with polatuzumab vedotin will be evaluated in participants with at least 2 prior lines of systemic therapy (3L+) for the treatment of R/R mantle cell lymphoma (MCL) and in participants with 2L+ R/R DLBCL.

Conditions

  • B-cell Non-Hodgkin Lymphoma

Interventions

  • Mosunetuzumab (IV)Drug

    Participants will receive intravenous (IV) mosunetuzumab.

  • Mosunetuzumab (SC)Drug

    Participants will receive subcutaneous (SC) mosunetuzumab.

  • Polatuzumab vedotinDrug

    Participants will receive IV polatuzumab vedotin.

  • TocilizumabDrug

    Participants will receive IV tocilizumab as needed.

  • RituximabDrug

    Participants will receive IV rituximab.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Tolerated Dose (MTD) of Mosunetuzumab in Combination with Polatuzumab VedotinTime frame: Cycle 1 to Cycle 2 (cycle length = 21 days)
  2. Recommended Phase II Dose of Mosunetuzumab in Combination with Polatuzumab VedotinTime frame: Cycle 1 to Cycle 2 (cycle length = 21 days)
  3. Percentage of Participants with Adverse Events (AE)Time frame: Baseline through approximately 90 days after last study treatment
  4. Best Objective Response Rate (ORR), Defined as CR or Partial Response (PR) at any Time, Based on PET-CT and/or CT Scan, as Determined by the Independent Review Committee (IRC) using Standard Criteria for NHLTime frame: Baseline up to approximately 60 months (assessed at screening and then every 3 months for the first year, then every 6 months until disease progression, start of new anti-cancer therapy, or withdrawal)

Locations

29 sites in 5 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham School of Medicine

    Birmingham, Alabama

  • City of Hope

    Duarte, California

  • University of Colorado Hospital - Anschutz Cancer Pavilion

    Aurora, Colorado

  • University of Miami Miller School of Medicine

    Miami, Florida

  • Moffitt Cancer Center

    Tampa, Florida

  • University of Michigan Hospital

    Ann Arbor, Michigan

  • Karmanos Cancer Institute

    Detroit, Michigan

  • New York University Langone Medical Center

    New York, New York

  • Levine Cancer Institute

    Charlotte, North Carolina

  • Penn State Milton S. Hershey Medical Center

    Hershey, Pennsylvania

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • University of Pittsburgh - Hillman Cancer Center

    Pittsburgh, Pennsylvania

  • Lifespan Cancer Institute

    Providence, Rhode Island

  • University of Texas M.D. Anderson Cancer Center

    Houston, Texas

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington

  • Medical College of Wisconsin, Froedtert Hospital;Nephrology Section

    Milwaukee, Wisconsin

  • UZ Brussel

    Brussels, Belgium

  • CH Jolimont - Lobbes (Jolimont)

    Haine-Saint-Paul, Belgium

  • Clinique St Pierre asbl

    Ottignies, Belgium

  • Hamilton Health Sciences - Juravinski Cancer Centre

    Hamilton, Ontario, Canada

  • Jewish General Hospital

    Montreal, Quebec, Canada

  • Saskatchewan Cancer Agency (SCA) - Saskatoon Cancer Centre (SCC)

    Saskatoon, Saskatchewan, Canada

  • Institut Catala d Oncologia Hospital Duran i Reynals

    Barcelona, Spain

  • Hospital de San Pedro de Alcantara

    Cáceres, Spain

  • Hospital General Universitario Gregorio Marañon

    Madrid, Spain

  • Hospital Infanta Leonor; Servicio de Hematologia

    Madrid, Spain

  • Hospital Universitario Virgen Macarena; Servicio de Oncologia

    Seville, Spain

  • Cambridge University Hospitals NHS Foundation Trust

    Cambridge, United Kingdom

  • Plymouth Hospitals NHS Trust; Pharmacy Dept

    Plymouth, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.